Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis

BACKGROUND: The purpose of this analysis was to investigate the effectiveness of afatinib compared to that of osimertinib in patients with non-small cell lung cancer (NSCLC) who harbored uncommon epidermal growth factor receptor (EGFR) mutations. METHODS: A PubMed database-based literature review wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chunsheng, Zhao, Kewei, Hu, Shanliang, Dong, Wei, Gong, Yan, Xie, Conghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243768/
https://www.ncbi.nlm.nih.gov/pubmed/37116899
http://dx.doi.org/10.1093/oncolo/oyad111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243768/
https://www.ncbi.nlm.nih.gov/pubmed/37116899
http://dx.doi.org/10.1093/oncolo/oyad111

Ejemplares similares